Home
Anne Margrete Øyan's picture

Anne Margrete Øyan

Researcher
  • E-mailAnne.Oyan@uib.no
  • Phone+47 55 58 45 01
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) 2021. Evaluation of β-catenin inhibition of axitinib and nitazoxanide in human monocyte-derived dendritic cells. Biomedicines. 1-18.
  • Show author(s) 2018. Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer. Nature Chemical Biology. 94-101.
  • Show author(s) 2018. Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLOS ONE. 1-21.
  • Show author(s) 2018. Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain. Pharmacology Research & Perspectives. 1-15.
  • Show author(s) 2017. Tumour-associated glial host cells display a stem-like phenotype with a distinct gene expression profile and promote growth of GBM xenografts. BMC Cancer. 1-13.
  • Show author(s) 2017. Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. OncoTarget. 106989-107001.
  • Show author(s) 2017. PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports. 1-12.
  • Show author(s) 2017. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
  • Show author(s) 2017. An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells. PLOS ONE. 1-20.
  • Show author(s) 2016. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. BMC Cancer. 15 pages.
  • Show author(s) 2016. Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer. Proceedings of the National Academy of Sciences of the United States of America. 9339-9344.
  • Show author(s) 2016. Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. OncoTarget. 9696-9707.
  • Show author(s) 2016. Androgen receptor as potential therapeutic target in metastatic endometrial cancer. OncoTarget. 49289-49298.
  • Show author(s) 2015. Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. OncoTarget. 39676-39691.
  • Show author(s) 2015. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. OncoTarget. 1327-1339.
  • Show author(s) 2015. Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. OncoTarget. 10634-10645.
  • Show author(s) 2015. ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. OncoTarget. 28440-28452.
  • Show author(s) 2014. Switch in FOXA1 status associates with endometrial cancer progression. PLOS ONE.
  • Show author(s) 2014. Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors. Molecular Cancer Research. 754-764.
  • Show author(s) 2014. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. OncoTarget. 1052-1061.
  • Show author(s) 2014. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. British Journal of Cancer. 78-84.
  • Show author(s) 2014. Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 599-606.
  • Show author(s) 2013. p63 attenuates epithelial to mesenchymal potential in an experimental prostate cell model. PLOS ONE. 12 pages.
  • Show author(s) 2013. MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. International Journal of Cancer. 544-555.
  • Show author(s) 2013. Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clinical Cancer Research. 1094-1105.
  • Show author(s) 2013. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLOS ONE. 9 pages.
  • Show author(s) 2013. High phospho-stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clinical Cancer Research. 2331-2341.
  • Show author(s) 2013. Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. Cancer Research. 7090-7100.
  • Show author(s) 2013. Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients. Cell Proliferation. 554-562.
  • Show author(s) 2013. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Modern Pathology. 428-434.
  • Show author(s) 2012. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 8699-8704.
  • Show author(s) 2012. Loss of GPER identifies new targets for therapy among a subgroup of ER alpha-positive endometrial cancer patients with poor outcome. British Journal of Cancer. 1682-1688.
  • Show author(s) 2012. Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer. 7 pages.
  • Show author(s) 2012. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. British Journal of Cancer. 1997-2004.
  • Show author(s) 2012. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLOS ONE.
  • Show author(s) 2012. Gene expression in tumor cells and stroma in dsRed 4T1 tumors in eGFP-expressing mice with and without enhanced oxygenation. BMC Cancer. 10 pages.
  • Show author(s) 2011. Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model. Experimental Cell Research. 234-247.
  • Show author(s) 2011. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. British Journal of Cancer. 921-926.
  • Show author(s) 2011. Gene Expression Patterns Related to Vascular Invasion and Aggressive Features in Endometrial Cancer. American Journal of Pathology. 861-871.
  • Show author(s) 2011. Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLOS ONE. 15 pages.
  • Show author(s) 2010. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. European Journal of Haematology. 239-251.
  • Show author(s) 2010. Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells. BMC Genomics. 15 pages.
  • Show author(s) 2009. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS - Journal of Pathologiy, Microbiology and Immunology. 575-582.
  • Show author(s) 2009. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. British Journal of Haematology. 53-68.
  • Show author(s) 2009. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors; release profile and pharmacological modulaion. European Journal of Haematology. 239-251.
  • Show author(s) 2009. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 53-68.
  • Show author(s) 2009. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America. 4834-4839.
  • Show author(s) 2009. Hyperoxic treatment induces mesenchymal to epithelial transition in a rat adenocarcinoma model. PLOS ONE.
  • Show author(s) 2009. Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype. Neuropathology and Applied Neurobiology. 380-393.
  • Show author(s) 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLOS ONE. 14 pages.
  • Show author(s) 2009. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer.
  • Show author(s) 2008. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia. 287-293.
  • Show author(s) 2008. Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. British Journal of Cancer. 1662-1669.
  • Show author(s) 2008. Epithelial to Mesenchymal Transition of a Primary Prostate Cell Line with Switches of Cell Adhesion Modules but without Malignant Transformation. PLOS ONE.
  • Show author(s) 2007. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 332-341.
  • Show author(s) 2007. Increased expression of sim2-s protein is a novel marker of aggressive prostate cancer. Clinical Cancer Research. 892-897.
  • Show author(s) 2007. Hyperoxia retards growth and induces apoptosis, changes in vascular density and gene expression in transplanted gliomas in nude rats. Journal of Neuro-Oncology. 191-202.
  • Show author(s) 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukamia cells indentify patient subgroups that differ susceptibility to histone deactylase inhibitors. International Journal of Oncology. 1529-1538.
  • Show author(s) 2007. ERG upregulation and related ETS transcription factors in prostate cancer. International Journal of Oncology. 19-32.
  • Show author(s) 2007. Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 46-58.
  • Show author(s) 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. International Journal of Oncology. 1065-1080.
  • Show author(s) 2006. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2 : Bax ratio and low levels of heat shock protein 70 and 90. Leukemia Research. 1531-1540.
  • Show author(s) 2006. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 16466-16471.
  • Show author(s) 2006. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clinical Cancer Research. 3985-3992.
  • Show author(s) 2005. Gene expression profiles in prostate cancer: Association with patient subgroups and tumour differentiation. International Journal of Oncology. 329-336.
  • Show author(s) 2005. CD34 expression in native human acute myelogenous leukemia blasts: Differences in CD34 membrane molecule expression are associated with different gene expression profiles. Cytometry. 18-27.
  • Show author(s) 2004. Nucleosome binding by the bromodomain and PHD finger of the transcriptional cofactor p300. Journal of Molecular Biology (JMB). 773-788.
Popular scientific lecture
  • Show author(s) 2005. Overexpression of ERG and SIM2 transcription factors in prostate cancer.
Academic lecture
  • Show author(s) 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
  • Show author(s) 2009. EMT Promotes Malignant Transformation of Prostate Epithelial Cells in Culture.
  • Show author(s) 2008. Polycomb group target genes and bivalent H3K4 & K27me3 modifications in human embryonic cells were enriched among dysregulated genes in prostate cancer.
  • Show author(s) 2008. Epithelial to mesenchymal transition of a primary, immortalized prostate cell line is associated with gene expression switches of entire cell attachment modules.
  • Show author(s) 2007. Functional oncogenomics and epigenomics analysis of prostate cancer.
  • Show author(s) 2007. Detection of TMPRSS2:ERG translocations in the urine of prostate cancer patients and identification of ERG target genes.
  • Show author(s) 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • Show author(s) 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • Show author(s) 2006. Global gene expression analysis of transcription factors in prostate cancer and cell lines.
  • Show author(s) 2006. ERG upregulation and related transcription factors in prostate cancer.
  • Show author(s) 2005. Discovering candidate genes that distinguish between CML and AML using microarrays.
  • Show author(s) 2004. Gene expression profiling in prostate cancer refined by pairwise comparisons of cDNA microarrays from benign and malignant tissue.
  • Show author(s) 2004. Gene expression profiles in prostate cancer: identification of upregulated SIM2 gene validated in archival tissue, relation to histological grading and prognosis.
  • Show author(s) 2003. The PHD finger, a protein domain involved in chromatin-based gene regulation.
  • Show author(s) 2003. Global analysis of gene expression and regulatory patterns in acute myeloid leukemia.
  • Show author(s) 2003. Gene expression profiling in prostate cancer: cluster analysis and association with tumor differentation.
Reader opinion piece
  • Show author(s) 2010. Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer. Histopathology. 641-646.
Doctoral dissertation
  • Show author(s) 2018. Regulatory patterns in prostate cell differentiation – investigation of transcription factors AR, GATA2 and NKX3-1.
  • Show author(s) 1994. Infection by herpes simplex virus: a study of the interaction between virus ligands and the cellular receptors. (dr. scient).
Academic chapter/article/Conference paper
  • Show author(s) 2017. Models of Tumor Progression in Prostate Cancer. 16 pages.
Abstract
  • Show author(s) 2013. FOXA1 LOSS IN ENDOMETRIAL CANCER IS ASSOCIATED WITH POOR PROGNOSIS AND ER ALPHA LOSS. International Journal of Gynecological Cancer. 1 pages.
  • Show author(s) 2011. TUMOR-ASSOCIATED GLIAL CELLS PROMOTE GROWTH OF GBM XENOGRAFTS IN EGFP NOD/SCID MICE. Neuro-Oncology. 55-55.
  • Show author(s) 2009. PRIMARY HUMAN ACUTE MYELOGENOUS LEUKEMIA CELLS SHOW CONSTITUTIVE RELEASE OF SEVERAL MATRIX METALLOPROTEASES AND THEIR INHIBITORS. Haematologica. 545-545.
  • Show author(s) 2007. Release of angiopoietin-1 by acute myelogenous leukemia (AML) cells is increased by stromal cells and associated with mutations in the nucleophosmin (NPM) gene. Experimental Hematology. 72-72.
  • Show author(s) 2007. Linking susceptibility to histone deactylase inhibitors and basal gene expression profiles in acute myeloid leukaemia. Experimental Hematology. 77-77.
  • Show author(s) 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in the susceptibility to histone deacetylase inhibitors. Haematologica. 112-112.
  • Show author(s) 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. NBS-nytt. 106.
  • Show author(s) 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy. International Journal of Molecular Medicine. S65.
  • Show author(s) 2006. Global gene expression analysis of transcription factors in prostate cancer and cell lines. International Journal of Molecular Medicine. S27.
  • Show author(s) 2006. ERG upregulation in relation to other transcription factors in prostate cancer. NBS-nytt. 72.
  • Show author(s) 2005. Single-minded 2 homolog gene is overexpressed in prostate cancer. Virchows Archiv. 432-432.
  • Show author(s) 2005. Overexpression of ERG and SIM2 transcription factors in prostate cancer. International Journal of Molecular Medicine. S76-S76.
Poster
  • Show author(s) 2020. Novel STAT3 inhibitors targeting STAT3 dimerization by binding to STAT3 SH2 domain.
  • Show author(s) 2013. TP63 regulation of EMT in an experimental prostate cell model.
  • Show author(s) 2013. Reactive oxygen species induce prostate cancer cells via activation of the IL6/STAT3 pathway. Abstract 304.
  • Show author(s) 2009. Suppression of heat shock Protein 27 induces long-term dormancy in human breast cancer.
  • Show author(s) 2009. Stepwise prostate carcinogenesis in vitro culture.
  • Show author(s) 2009. Stathmin is superior to AKT and Phospho-AKT staining to detect PI3Kinase activation and aggressive endometrial cancer.
  • Show author(s) 2009. Hyperoxic Treatment induces Mesenchymal-to-Epithelial Transition in a Rat Adenocarcinoma Model.
  • Show author(s) 2009. Highly infiltrative brain tumors show reduced chemosensitivity associated with a stem cell-like phenotype.
  • Show author(s) 2009. Global profiling of histone and DNA methylation reveals epigenetic-based gene regulation during EMT and transformation in a prostate cell model.
  • Show author(s) 2009. Global profiling of histone and DNA methylation reveals epigenetic-based gene regulation during EMT and transformation in a prostate cell model.
  • Show author(s) 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
  • Show author(s) 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
  • Show author(s) 2009. Epithelial to mesenchymal transition of a primary prostate cell line before malignant transformation with switches of cell adhesion modules.
  • Show author(s) 2009. A novel model of stepwise prostate carcinogenesis in culture.
  • Show author(s) 2008. Polycomb (PcG) targets are enriched in repressed genes in prostate cancer.
  • Show author(s) 2007. Patterns of gene expression related to vascular invasion and aggressive features in endometrial cancer.
  • Show author(s) 2007. Patterns of gene expression related to vascular invasion and aggressive features in endometrial cancer.
  • Show author(s) 2007. Early gene expression signature of chemotherapy treated acute myeloid leukemia in vivo.
  • Show author(s) 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation.
  • Show author(s) 2006. Single-minded 2 homolog (SIM2) is overexpressed in prostate cancer.
  • Show author(s) 2006. Gene expression profiles identify an aggressive phenotype in endometrial carcinoma.
  • Show author(s) 2006. ERG upregulation in relation to other transcription factors in prostate cancer.
  • Show author(s) 2005. Very high expression of specific transcription factors in prostate cancer compared with paired benign prostate tissue.
  • Show author(s) 2005. Single-minded 2 homolog gene (SIM2) is overexpressed in prostate cancer.
  • Show author(s) 2005. ETS transcription factors in prostate cancer.
  • Show author(s) 2005. Analysis of treatment response in acute myeloid leukemia patients using DNA microarrays.
  • Show author(s) 2003. The PHD finger of the transcriptional coactivator p300 binds nucleosomes in vitro.
  • Show author(s) 2002. The PHD finger: A protein domain involved in chromatin-based gene regulation.
Academic literature review
  • Show author(s) 2009. Tumor virology - history, status and future challenges. APMIS - Journal of Pathologiy, Microbiology and Immunology. 382-399.
  • Show author(s) 2007. Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in Acute Myeloid Leukemia. Current Pharmaceutical Biotechnology. 344-354.
  • Show author(s) 2007. Early gene expression of acute myeloid leukemia in response to chemotherapy. Expert Review of Anticancer Therapy. 741-751.

More information in national current research information system (CRIStin)